The FDA's July 2026 final guidance for sponsors running psychedelic drug trials, plus the September 14, 2026 public hearing on future therapeutic use — what the agency will and will not take comment on.
On July 14, 2026, the FDA’s Center for Drug Evaluation and Research (CDER) announced the availability of a final guidance for industry titled “Psychedelic Drugs: Considerations for Clinical Investigations.” A guidance document is not a regulation with the force of law. It is the agency’s statement of its current thinking on how sponsors should design studies to meet existing legal requirements for drug approval. Sponsors can depart from a guidance document, but doing so typically means a harder conversation with FDA reviewers about why an alternative approach still meets the underlying statutory standard.
This particular guidance is notable for what it is not: a brand-new document written from scratch. It finalizes a draft guidance the FDA first published in June 2023, meaning industry, academic sponsors, and patient advocates have had over three years to submit comments and watch the agency refine its thinking before this version became official.
FDA guidance documents are faster to issue and revise than formal regulations because they skip the notice-and-comment rulemaking required for binding rules. For a fast-evolving field like psychedelic drug development, where trial design questions (like how to blind a study when participants can often tell whether they received an active dose) are still being worked out in real time, a guidance lets FDA set expectations without locking in a rigid rule that would be hard to update as the science matures.
The finalized guidance sets evidentiary standards for New Drug Applications (NDAs) across three specific areas.
Most psychedelic drug trials struggle with a structural problem: participants can usually tell whether they received an active dose because the subjective effects are hard to miss, which undermines the blinding that placebo-controlled trials depend on for credible results. FDA’s Complete Response Letter rejecting Lykos Therapeutics’ MDMA application in August 2024 cited exactly this problem, functional unblinding, as one of its central concerns. This guidance is the agency’s formal response, telling sponsors what steps (such as active-placebo designs, independent outcome assessors blinded to treatment status, and pre-specified unblinding-rate reporting) it expects to see addressed in a submission.
Because psychedelics are Schedule I controlled substances, any approved drug product would also need a DEA scheduling determination alongside FDA approval. The guidance directs sponsors to build abuse-potential assessments into their clinical development programs early, not as an afterthought once Phase 3 data are in hand, so that the eventual DEA rescheduling review has the data it needs without adding years to the process after FDA approval.
A REMS is a set of controls the FDA can require after approval to manage a specific safety risk, such as certified-prescriber programs or supervised administration requirements. The guidance signals that FDA expects most approved psychedelic drug products to carry some form of REMS given supervised-administration risk, a detail with direct commercial consequences, since a REMS with certified-site requirements shapes how (and how widely) a drug can actually be distributed once approved, not just whether it gets approved.
The same July 14, 2026 Federal Register notice that announced the final guidance also scheduled a separate public hearing: “Considerations for Potential Future Therapeutic Use of Psychedelic Drugs,” docketed as FDA-2026-N-7542.
The hearing runs September 14, 2026, from 12:30 p.m. to 4:30 p.m. Eastern Time, in a hybrid format allowing both in-person and virtual attendance and testimony.
| Item | Detail |
|---|---|
| Hearing date | September 14, 2026, 12:30–4:30 p.m. ET |
| Format | Hybrid (in-person and virtual) |
| Docket number | FDA-2026-N-7542 |
| Request-to-present deadline | August 21, 2026, 11:59 p.m. ET |
| Written comment deadline | October 5, 2026 |
| Companion action | Final guidance, “Psychedelic Drugs: Considerations for Clinical Investigations” |
The hearing notice draws a sharp, deliberate line around its own scope, a detail that matters more to advocates than the hearing date itself. FDA explicitly excludes comments on legalization, decriminalization, the merits of state and local psychedelic programs, drug scheduling, and religious or ceremonial use.
At the same time, the notice explicitly welcomes data drawn from existing state programs, such as Oregon’s Measure 109 or Colorado’s Proposition 122, as a source of clinical outcome evidence. The distinction FDA is drawing is between policy advocacy (out of scope) and empirical data (in scope): a state program’s real-world outcome numbers can inform FDA’s thinking about therapeutic use, but arguments about whether that program should exist cannot.
The guidance and hearing land differently depending on where someone sits in the psychedelic drug development or policy landscape.
Drug sponsors (companies like Compass Pathways, Usona Institute, and Transcend Therapeutics) now have a final, rather than draft, standard to design remaining trials against, reducing regulatory uncertainty for any NDA submitted after July 14, 2026. See our FDA priority review voucher guide for how three of these programs are separately moving through expedited review.
Researchers running VA-sponsored or academic trials, such as the VA’s PIVOT psilocybin study and the VA MDMA study, gain a clearer template for the unblinding and safety-reporting standards their own protocols should meet, even though government-funded IND research and commercial NDA submissions follow separate regulatory tracks.
Patients and veterans tracking legal access timelines should treat the guidance as a process milestone, not an access milestone: it changes what evidence FDA will accept, not whether psilocybin or MDMA is legal to prescribe today.
The guidance does not reschedule any psychedelic under the Controlled Substances Act. Psilocybin, MDMA, LSD, DMT, and ibogaine remain Schedule I federally. A DEA rescheduling action can only begin after a specific drug product, not a compound in the abstract, receives FDA approval, and that process has historically taken 12–18 months on its own.
The guidance also does not approve any drug, set a guaranteed approval timeline, or bind FDA to a specific outcome for any pending application. It tells sponsors what evidence to bring; it does not pre-judge whether that evidence, once submitted, will be sufficient.
For the current complete picture of what is and is not legal today, see our guide to what psychedelics are legal in the US and the legal status by state tool.
"Psychedelic Drugs: Considerations for Clinical Investigations" is a final guidance document the FDA's Center for Drug Evaluation and Research published on July 14, 2026. It sets evidentiary standards for sponsors developing psychedelic drugs, covering how to mitigate functional unblinding, how to evaluate abuse potential, and what post-marketing risk evaluation and mitigation strategies (REMS) should look like. It finalizes a draft the FDA first issued in June 2023.
The FDA's public hearing, titled "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs," is scheduled for September 14, 2026, from 12:30 p.m. to 4:30 p.m. Eastern Time, in a hybrid in-person and virtual format. It is docketed under FDA-2026-N-7542.
Not directly as a policy argument. The FDA's notice explicitly excludes comments on legalization, decriminalization, the merits of state and local programs, drug scheduling, and religious or ceremonial use from the hearing's scope. The agency does welcome outcome data drawn from state programs, such as Oregon's or Colorado's, as clinical evidence. The distinction is between policy advocacy, which is out of scope, and data submission, which is in scope.
Requests to present at the hearing must be submitted through the FDA's meeting registration page by 11:59 p.m. Eastern Time on August 21, 2026. Written comments to the docket may be submitted through October 5, 2026, whether or not you register to speak.
No. The guidance sets clinical-trial evidentiary standards for FDA drug review. It does not touch the Controlled Substances Act scheduling of psilocybin, MDMA, or any other psychedelic. Scheduling changes require a separate DEA rescheduling process that can only begin after a specific drug product receives FDA approval.
Our legalization tracker follows FDA milestones, executive orders, state bills, and DEA scheduling actions, updated automatically.
Get FDA Psychedelic Drugs Clinical Investigation Guidance updates
New votes, rules, court rulings, and access changes for FDA Psychedelic Drugs Clinical Investigation Guidance — delivered when they happen.
← Back to all psychedelic laws
Suggest a tool, topic, or improvement that would make this site more useful.